411 results on '"Morari, Michele"'
Search Results
2. NOP Receptor Ligands and Parkinson’s Disease
3. Dopamine neuron dysfunction and loss in the PrknR275W mouse model of Juvenile Parkinsonism
4. Modeling Parkinson’s disease in LRRK2 rodents
5. Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity
6. Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release
7. NOP Receptor Ligands and Parkinson’s Disease
8. Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4
9. d-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain
10. Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism
11. Anti‐Parkinsonian and anti‐dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists
12. Regulator of G‐Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for l‐Dopa‐induced dyskinesia.
13. Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson’s disease
14. Nociceptin/Orphanin FQ Modulates Neurotransmitter Release in the Substantia Nigra: Biochemical and Behavioural Outcome
15. Changes of Glutamatergic Control of Striatal Acetylcholine Release in Experimental Parkinsonism
16. LRRK2 modulates neuronal vesicles cycle through protein interactions
17. Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice
18. Nanoparticulate lipid dispersions for bromocriptine delivery: Characterization and in vivo study
19. In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to l-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels
20. Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology
21. Modeling Parkinson's disease in LRRK2 mice: focus on synaptic dysfunction and the autophagy-lysosomal pathway
22. Regulator of G‐Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for l ‐Dopa‐induced dyskinesia
23. In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity
24. Dopamine–nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: Involvement of D 2/D 3 receptors and impact on nigro-thalamic neurons and motor activity
25. Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo
26. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity
27. Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxical inhibition is relieved by D 2/D 3 receptor blockade
28. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinsonʼs disease
29. Early Dysfunction of Substantia Nigra Dopamine Neurons in the ParkinQ311X Mouse
30. LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation
31. Solid Lipid Nanoparticles as Delivery Systems for Bromocriptine
32. RGS4 negatively modulates Nociceptin/Orphanin FQ opioid receptor signaling: implication for L-Dopa induced dyskinesia
33. Mitochondrial P2X7 Receptor Localization Modulates Energy Metabolism Enhancing Physical Performance
34. Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats
35. Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands
36. Modeling Parkinson’s disease in LRRK2 mice: focus on synaptic dysfunction and the autophagylysosomal pathway.
37. Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson’s disease
38. L-DOPA impairs proteasome activity in parkinsonism through D1 dopamine receptor
39. Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels
40. Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: Involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity
41. The P2X7 receptor localizes to the mitochondria, modulates mitochondrial energy metabolism and enhances physical performance
42. 6‐Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata
43. Pharmacological Antagonism of Kainate Receptor Rescues Dysfunction and Loss of Dopamine Neurons in a Mouse Model of Human Parkin-induced Toxicity
44. Translation Imaging in Parkinson’s Disease: Focus on Neuroinflammation
45. Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease
46. Discovery and Structure–Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson’s Disease Models
47. Managing Parkinson's disease: moving ON with NOP
48. Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinsonʼs disease: a behavioral and neurochemical study in reserpinized mice
49. Brain Interstitial Nociceptin/Orphanin FQ Levels are Elevated in Parkinsonʼs Disease
50. Autophagy and LRRK2 in the Aging Brain
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.